Strategic partnership Aenitis has recently entered a Memorandum of Understanding with Bracco Imaging, highlighting a potential collaboration trail to expand applications of acoustofluidic technology in medical imaging and contrast agent workflows.

Funding traction With European H2020 SME Instrument funding secured in the past and current revenue between $1M-$10M, there is validated investor confidence and a track record that can support expanded commercial outreach and larger pilot programs.

Clinical scalability Mitis enables gentle, scalable, contact-free processing capable of handling tens of milliliters per minute, aligning with needs of cell and gene therapy manufacturing and potential integration into contract manufacturing organizations.

Strategic customers Existing collaborations with Mercodia for functional testing and the Bracco partnership position Aenitis to pursue life sciences customers spanning research labs, biotech startups, and clinical-scale manufacturing partners.

Global enablement European Commission and French Government support, coupled with flagship investors like EIB and Seventure, suggest favorable policy and funding environments that can facilitate international expansion and multi-country pilots.